臨床研究等提出・公開システム

A phase II clinical trial of KNP2002 ointment in patients with common warts

A phase II clinical trial of KNP2002 ointment in patients with common warts

Sato Katsuhiko

KinoPharma Inc.

3-11-5 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023, Japan

k.sato@kinopharma.com

Sato Katsuhiko

KinoPharma Inc.

3-11-5 Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023, Japan

+81-3-6264-9604

k.sato@kinopharma.com

Not Recruiting

June. 05, 2023

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

1. Subjects aged 15 to 49 at the time of obtaining consent
2. Subjects with typical common warts on the upper extremities or lower extremities excluding the soles of the feet.
3. Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration
4. Subjects who have given their voluntary written consent to participate in this clinical trial

1. Subjects with 5 or more warts due to human papillomavirus (HPV) infection on the upper or lower limbs
2. Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts
3. Subjects with a history of allergy to topical skin preparations
4. Subjects with a history of malignant tumor within 5 years before administration of study drug
5. Subjects with any of the following diseases
Malignant tumor
Serious heart disease
Poorly controlled diabetes, hypertension
6. Women who are pregnant, may become pregnant, or are breastfeeding.

Both

Common warts

The following 4 groups will be administered, and KNP2002 is administered repeatedly for 12 weeks.
KNP2002 high dose
KNP2002 moderate dose group
KNP2002 low dose group
Placebo group

KNP2002

1. Safety evaluation items
Adverse event
2. Efficacy endpoints
Wart area change from the start of administration (at endpoint)

1. Change in wart area over time
2. Wart disappearance rate
3. Wart improvement rate

May. 17, 2023

No

none